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Abstract 
Atrial fibrillation (AF) is the most common arrhythmic disorder world-wide, accounting for 15 % of all strokes. Manage-
ment of stroke risk in AF is complicated by intolerance of anti-coagulation (AC) therapy and difficulty maintaining 
therapeutic range in patients treated with warfarin. The left atrial appendage (LAA) is a source of thrombus in AFre-
lated thrombo-embolic events and surgical LAA exclusion (LAAO) is commonly performed during cardiac surgery 
in AF patients. Surgical approaches are limited by a high incidence of incomplete closure with a potential for conse-
quent thrombo-embolic events as well as the morbidity of an open-heart procedure. More recently, percutaneous 
approaches to LAAO have been developed. The LARIAT device is an epicardial LAA exclusion system that enables 
percutaneous suture ligation of the LAA via combined, pericardial and trans-septal access. The device has 510k Fed-
eral Drug Administration (FDA) clearance for soft-tissue ligation and has been studied in canine models in pre-clinical 
studies as well as published series of clinical experience with LARIAT LAAO. The history, patient selection, procedural 
technique and complications of LARIAT LAAO are reviewed here. Additionally, insights and procedural improve-
ments that have been elucidated from clinical series and outcomes from the collective experience are discussed. The 
LARIAT’s epicardial approach to LAA ligation is unique compared with other percutaneous LAA exclusion devices, 
however more data regarding device safety and efficacy is needed for the LARIAT to emerge as an established therapy 
for stroke prevention in AF.
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Background
Atrial fibrillation (AF) is the most common arrhythmic 
disorder worldwide, affecting approximately 2.3 million 
people in the United States and 4.5 million in the Euro-
pean Union (January et  al. 2014). With age, the preva-
lence and disease burden of AF increases, accounting for 
15  % of all strokes and with greater associated morbid-
ity and mortality than non-AF related strokes (January 
et  al. 2014; Connolly et  al. 2009). Oral anti-coagulation 
(AC) is the mainstay of stroke prevention therapy but 
is complicated by bleeding events and prescribing com-
plexity, with only 50–60 % of patients treated with war-
farin consistently in therapeutic range (Go et  al. 1999). 
New oral anti-coagulants (NOACs) such as the direct 
thrombin inhibitor, dabigatran, and factor Xa inhibitors, 
rivaroxaban and apixaban, provide consistent AC com-
pared with Coumadin but are limited by bleeding com-
plications, expense and inability to expeditiously reverse 
these agents during an acute bleeding event (Connolly 
et al. 2009; Patel et al. 2011; Granger et al. 2011). These 
challenges have led to a focus on alternate therapies to 
reduce stroke risk in patients with AF.
The left atrial appendage (LAA) has a narrow-orifice 
with a tubular, trabeculated structure that fibrillates 
rather than contracts in AF, resulting in blood stasis and 
predisposition to thrombus formation (Al-Saady et  al. 
1999; Kanmanthareddy 2014). In a meta-analysis of 23 
studies of AF patients, thrombus, when present, was 
localized to the LAA in 91 % of patients with non-valvu-
lar AF. The implication of the LAA as a primary source 
of thrombus for thrombo-embolic events in non-valvular 
AF has made it a veritable target for stroke reduction.
Surgical LAA exclusion by excision or ligation of the 
LAA, when combined with the Cox-Maze procedure, has 
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demonstrated proficiency in reducing subsequent stroke 
risk (Bonow et al. 2008; Cox et al. 1999). Notably, a 36 % 
incidence of incomplete exclusion with surgical ligation 
alone has been observed and associated with thrombus 
formation in the partially excluded LAA as well as sub-
sequent thrombo-embolic events (Katz et al. 2000). The 
flaccid state of the LAA on cardiac bypass and proxim-
ity of the circumflex artery to the base of the LAA, have 
been proposed etiologies of sub-optimal success with 
surgical approaches. Excision of the LAA provides more 
consistent results and the 2014 AHA/ACC/HRS Guide-
lines for the management of atrial fibrillation provide a 
Class IIB/Level of Evidence C, recommendation for sur-
gical excision of the LAA in patients undergoing cardiac 
surgery (January et al. 2014). However, surgical excision 
remains limited by the morbidity of an open-heart proce-
dure and lack of robust efficacy data. Surgical experience 
has inspired and informed the development of percuta-
neous left atrial appendage occlusion (LAAO) devices. 
The LARIAT ligation system is currently the most stud-
ied percutaneous epicardial LAAO device.
LARIAT ligation
Device development
The LARIAT device was developed by a cardiothoracic 
surgeon and has United States Federal Drug Administra-
tion (US FDA) 510k clearance for the indication of soft-
tissue approximation with greater than 2000 implants 
world-wide for LAA ligation (Price and Gibson 2014). A 
second generation of the device accommodating larger 
LAAs is also now commercially available. The LARIAT 
system accomplishes percutaneous delivery of a suture 
that snares the LAA epicardially, at its os, via trans-septal 
and pericardial access. Pre-clinical canine studies dem-
onstrated angiographic LAA exclusion utilizing LAR-
IAT LAAO, confirmed by macroscopic evaluation and 
showed progressive LAA atrophy and endothelialization 
of the LAA orifice in a time-dependent manner from liga-
tion (Lee et al. 2010). The utility of an endoluminal, bal-
loon, placed at the os of the LAA to guide LARIAT snare 
placement and prevent suture slippage was elucidated 
in an animal trial as well (Singh et al. 2010). Subsequent 
clinical trials have led to the use of LARIAT ligation most 
widely for an off-label indication of left atrial appendage 
ligation for stroke reduction.
Patient selection
Patient selection (Table  1) for the LARIAT LAAO is 
guided by the initial safety and feasibility trial com-
pleted by Bartus et  al. and by experiences published by 
early operators (Price and Gibson 2014; Stone et al. 2013; 
Bartus et  al. 2013; Massumi et  al. 2013). Bartus et  al. 
included: AF patients with a CHADS2 score of ≥1 with 
one of: (1) contraindication to AC, including gastrointes-
tinal, intra-cerebral, urologic or pulmonary bleeding, (2) 
cerebrovascular accident (CVA) despite adequate AC or 
(3) indication for ‘triple-therapy’ with aspirin, thienopyri-
dine and AC with high bleeding risk (Bartus et al. 2013).
Contraindications include prior pericarditis or peri-
cardiotomy and thoracic radiation, as pericardial adhe-
sions complicate pericardial access required for LARIAT 
LAAO. Due to appendage manipulation during the pro-
cedure, active thrombus within the LAA is also contrain-
dicated. Additionally, Bartus et al. excluded patients with 
a myocardial infarction within 3  months, thromboem-
bolic event within 30 days, New York Heart Association 
(NYHA) Class IV heart failure and left ventricular ejec-
tion fraction <30 %.
LARIAT candidates undergo an anatomical evaluation 
with a cardiac-gated, computed tomography (CT) scan 
with contrast and 3D image reconstruction to evaluate 
for anatomical exclusions that preclude successful device 
advancement. These include: (1) LAA width >40 mm, (2) 
superiorly oriented LAA with the apex directed behind 
the pulmonary artery (PA), (3) multi-lobed LAA in which 
lobes are oriented in different planes exceeding 40 mm, 
and (4) posteriorly rotated heart.
Procedure
The LARIAT procedure has been extensively detailed as 
have recommendations to minimize complications and 
optimize outcomes (Lee et  al. 2010; Singh et  al. 2010; 
Bartus et al. 2011, 2013; Valderrabano 2014; Price 2014; 
Koneru et al. 2014). LARIAT LAAO typically takes place 
in a cardiac catheterization laboratory (CCL), electro-
physiology laboratory (EPL) or hybrid operating room 
and is implanted by electrophysiologists and interven-
tional cardiologists under general anesthesia with trans-
esophageal echocardiography (TEE) guidance. The 
procedure requires optimal pericardial access described 
in Figs.  1 and 2 as well as trans-septal access. Ligation 
occurs with advancement of the LARIAT device via 
the pericardial sheath over a rail system created by the 
attached endocardial and epicardial guidewires, followed 
by snare-capture of the LAA.
A pericardial drain is typically left in place and 
removed the following day if output is minimal. Patients 
are discharged 24–48 h after uncomplicated implantation 
and surveillance TEE is performed at 4–6  weeks post-
implant. Pain management approaches include Tylenol 
as well non-steroidal anti-inflammatory agents. Sched-
uled colchicine for 2  weeks following LARIAT ligation 
has been effective in reducing the incidence of post-pro-
cedural pericarditis and pain. Anti-platelet and AC regi-
mens following LARIAT ligation in published experience 
are variable with some patients continued on AC therapy 
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if tolerated, others treated with Aspirin or Plavix or both 
for a period of time (Koneru et al. 2014).
Imaging
Laura et  al. have detailed the role of multi-modality 
imaging during LARIAT ligation (Laura et  al. 2014). A 
contrast, cardiac-gated CT is utilized to plan pericardial 
access and provides information regarding anatomical 
features such as pulmonary artery enlargement, large 
xiphoid process or tight retrosternal space and delineates 
the course of the phrenic nerve and internal mammary 
artery. CT can also exclude thrombus pre-procedurally 
as well as indicate the presence of accessory LAAs or 
diverticula (Ismail et al. 2015). TEE confirms the absence 
of LAA thrombus, guides placement of the snare at the 
LAA os by allowing endocath balloon visualization and 
provides surveillance for pericardial effusion develop-
ment during the procedure (Fig. 3). TEE and LA angiog-
raphy are utilized for confirmation of closure, to assess 
for residual jets immediately post-procedure and to guide 
further suture tightening (Fig. 4).
Peri‑procedural complications
Complications during LARIAT LAAO can occur dur-
ing trans-septal, pericardial or venous access as well as 
during LARIAT delivery. Technical approaches to pre-
vent LARIAT LAAO complications are summarized in 
Table 2 (Price 2014).
Pericardial effusion and tamponade from RV punc-
ture or abrasion during sheath advancement can 
complicate pericardial access. Coronary or epigastric 
artery laceration, trauma to intra-abdominal organs 
and pleural puncture have also been observed with 
LARIAT LAAO but should be avoidable with review 
of pre-procedural CT (Price and Gibson 2014; Stone 
et al. 2013). Utilizing a micro-puncture needle for per-
icardial access may mitigate the risk of significant RV 
laceration. When encountered, adhesions should lead 
to consideration for aborting ligation given low likeli-
hood of procedural success in this setting and higher 
risk of complication. Effusions should be promptly 
Fig. 1 Advancement of the pericardial access needle with small 
injections of dye allows recognition of pericardial access site with 
tenting of the pericardium
Fig. 2 Pericardial access planning in the AP and LL projections. a In the AP projection, Kelley clamps are placed below the sub-xiphoid process and 
at the likely position of the LAA (Δ) based on the position of the PA (*). The ideal trajectory of trans-septal sheath placement is lateral to the LAA in 
the region between the dashed red arrows. b In the LL view, the pericardial silhouette (orange dashed line) can be approximated by performing a 
right ventriculogram outlining the RV endocardium. The anterior pericardium is entered following the tract of the dotted yellow arrow. The xiphoid 
process tip is noted at the short red arrow
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Table 1 LARIAT LAAO patient selection (Bartus et al. 2013)
INR international normalized ratio, CVA cerebrovascular accident
Clinical inclusion recommendations Clinical exclusion recommendations Anatomical exclusion recommendations
Atrial fibrillation with CHADS2 score ≥1 History of prior cardiac surgery
Myocardial infarction within 3 months
LAA width >40 mm
Contraindication to AC therapy including: History of pericarditis Superiorly oriented LAA with the LAA apex 
directed behind the pulmonary trunk
 Gastrointestinal bleeding History of thoracic radiation Multi-lobed LAA in which lobes are oriented in 
different planes exceeding 40 mm
 Intra-cranial bleeding Pectus Excavatum Posteriorly rotated heart
 Urologic bleeding Thromboembolic event within 1 month
 Pulmonary bleeding New York Heart Association Class IV heart failure
Recurrent CVA despite adequate AC therapy Left ventricular function <30 %
Requirement for aspirin, thienopyridine therapy 
and AC therapy with high-bleed risk
Intolerance to AC therapy
Fig. 3 a The dashed line indicates the desired ligation site, just inferior to the Coumadin ridge (arrow). b The proximal end of the balloon is posi-
tioned at the LAA orifice under TEE guidance. The radio-opaque marker at the proximal end of the balloon (arrow) guides advancement of the 
LARIAT system over the LAA os under fluoroscopy; PV pulmonary vein
Fig. 4 a LA angiography post LARIAT LAAO without flow into the snared LAA b TEE demonstrating residual 1 mm jet of flow into the ligated LAA 
(yellow arrow)
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treated with drainage and reversal of AC as well as 
consideration for surgery and can be managed antici-
patorily with placement of an extra ‘bail out’ wire in 
the pericardial space to provide pericardial access for 
expedited drainage of a large effusion (Price 2014). 
Late pericardial effusions may develop and are hypoth-
esized to result from inflammation related to LAA 
necrosis. Late pleural effusions have also been noted 
and may be transudative or exudative and potentially 
represent volume retention from reduced atrial natriu-
retic peptide (ANP) release after LAA ligation (Gunda 
et al. 2015).
Traction forces on the LA during LARIAT advance-
ment and suture tightening can lead to LAA laceration 
or perforation and need for surgical rescue. Keating 
et  al. reported LA laceration and cardiac tamponade 
requiring surgical intervention in 3 of 6 LARIAT liga-
tions performed at their center (Keating et  al. 2014). 
Reducing catheter prolapse onto the LA, particularly 
when the LA is enlarged, is a recommended preventa-
tive practice for LA or LAA laceration. Deployment of 
the LARIAT at a position with sufficient laxity such 
that the appendage orifice is recreated by proximal 
LAA tissue results in lesser traction on neighboring 
LA tissue. LAA perforation can occur during con-
nection of the endo- and epi- wires, when tension 
imposed on the friable LAA can cause the epicardial 
wire to perforate. While prompt LARIAT deploy-
ment is a definitive treatment for LAA laceration or 
perforation, surgical readiness and a low threshold for 
surgical evaluation of ongoing pericardial output is 
recommended to avoid rapid decompensation.
Clinical experience and outcomes
Results of the published clinical experience with the LAR-
IAT device with greater than ten patients are reviewed 
in Tables  3, 4 and cumulative event rates of series only 
closed-chest ligation are summarized in Table 5.
The first-in-man feasibility study of the LARIAT device 
evaluated 13 patients undergoing LARIAT ligation either 
during open-heart surgery or in a closed-chest fashion. 
Twelve of 13 patients in this series had successful LAA 
ligation with 1 patient in whom the procedure was ter-
minated due to lack of adequate echocardiographic guid-
ance for snare advancement. Notably, a patient with 
pectus excavatum required a thoracoscopic procedure 
for device removal due to sternal compression (Bartus 
et al. 2011).
Bartus et  al. subsequently published experience with 
LARIAT ligation in 92 patients from a single center, 
where ligation was successfully completed in 85 of 92 or 
93 % of subjects. At 1-year follow-up, 65 patients under-
went follow-up TEE with all patients having <5 mm leak. 
Notably, 55 % of the patients in this series were continued 
on AC therapy (Bartus et al. 2013).
Massumi et  al. reported the first series of LARIAT 
ligation performed in the (US) in a single-center report 
of 20 patients. All attempted ligations were success-
ful however peri-procedurally, 1 patient required sur-
gical intervention for RV perforation and 1 patient was 
treated with pericardiocentesis for tamponade physiol-
ogy. All 17 patients undergoing follow-up TEE at a mean 
of 96  ±  77  days had persistent LAA occlusion. How-
ever, in 6 of 17 patients, a small pouch was noted at the 
LAA os, containing smooth muscle tissue in 5 patients 
Table 2 Potential prevention strategies for procedural complications of LARIAT LAAO (Price 2014; Keating et al. 2014)
TSP trans-septal puncture, IAS inter-atrial septum, RV right ventricle
Complication Cause Preventative strategy
Pericardial effusion Initial TSP
Guide wire or catheter trauma to LAA after TSP
Manipulation of delivery system in pericardium
Pericardial access
TEE guidance
Avoidance of severe IAS tenting
Advancement of trans-septal sheath dilator into LAA under 
fluoroscopy over 0.32″ wire with distal curve on coronary 
wire
TEE surveillance for RV compression with sheath advance-
ment to avoid RV abrasion
Micro-puncture access needle
Placement of a ‘bail out’ wire in the pericardium for quick 
pericardial drain placement
LAA laceration or perforation LARIAT advancement and deployment Cognizance of endocardial and epicardial wire forces on 
LAA
Minimization of LARIAT delivery system prolapse onto LA
Careful suture tightening





Careful flushing of trans-septal sheath
Vascular complications Hematoma, arterio-venous fistula, pseudoaneurysm, 
bleeding, hematoma
Careful technique with ultrasound guidance as needed
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and pectinate muscles in one patient. Involution of the 
excluded LAA was noted in 3 patients in whom follow-
up CT imaging was performed (Massumi et al. 2013).
Stone et al. reported a series of 27 US patients, selected 
from 42 patients being evaluated for LAAO that under-
went LARIAT ligation, with 25 of 27 having successful 
ligation. One peri-procedure stroke was attributed to a 
sub-therapeutic ACT with thrombus noted on the trans-
septal sheath. All 22 patients completing follow-up TEE 
at a mean of 45  days had durable ligation (Stone et  al. 
2013).
The largest US LARIAT experience studied 154 con-
secutive patients undergoing LAA ligation at eight 
centers. Device success, defined as device deployment 
with <5 mm residual leak by TEE, was achieved in 94 % 
of patients. Major bleeding occurred in 9 % of patients, 
and peri-procedural pericardial effusion in 16  %. 
Despite similar device success rates as other series, a 
higher rate of late-leak (20 %) and LA thrombus (4.8 %) 
was noted in follow-up. Of note, the patients included 
in this study were older and had more co-morbidities 
than the initial single center study of Bartus et al. (Price 
et al. 2014).
Miller et  al. reported on an additional 41 consecutive 
patients undergoing LARIAT ligation with 39/41 having 
procedural success. A high rate of pericardial effusions 
requiring pericardiocentesis post-procedurally was noted 
(20  %), which authors attributed to operators in this 
series not maintaining a pericardial drain post-procedur-
ally. Seven percent of patients required thoracentesis for 
late pleural effusions. Authors also noted a high rate of 
LAA perforation, with 2 of 4 patients with this compli-
cation requiring surgical treatment. All 4 patients with 
LAA perforation required multiple attempts to position 
the LARIAT snare, suggesting that in cases of challeng-
ing anatomy, advancement should be attempted when 
endocardial and epicardial wire alignment is optimal and 
aborted after a limited number of attempts to avert lac-
eration and perforation (Miller et al. 2014).
Gafoor and authors evaluated the safety and efficacy 
of LAAO with a number of occlusion devices in a cohort 
of 75 octogenarians. Procedural success was noted in all 
4 patients undergoing LARIAT exclusion, with no acute 
adverse safety events and an average hospital length 
of stay of 2.5  days. At 1-year, 1 LARIAT patient had 
an embolic stroke with thrombus originating from an 
incompletely ligated lobe of the appendage (Gafoor et al. 
2014).
Patel et  al. evaluated the compassionate use of LAR-
IAT ligation in 9 patients who were precluded based on 
appendage morphology and size. Their analysis showed 
a LARIAT deployment success rate of 78  % utilizing 
strategies such as using the magnet-tipped endowire to 
straighten the LAA to reduce circumference and utiliz-
ing the endocath balloon to suction from the LAA, effec-
tively reducing LAA volume (Patel et al. 2015).
The FDA’s Manufacturer and User Facility Device Expe-
rience (MAUDE) reports 38 LARIAT-related adverse 
events from January 2012 to March 2015, including 31 
instances requiring emergent sternotomy for bleeding 
complications following LARIAT attempts, 4 deaths and 
1 episode of unexplained VT linked to myocardial scar 
after LARIAT ligation (Fig. 5). LA/LAA laceration or per-
foration accounted for 66 % of reported events, with LA/
LAA laceration most commonly resulting from multiple 
attempts at advancing the suture delivery system over the 
LAA while perforation most commonly resulted from 
endowire trauma.
Discussion
Several features distinguish the LARIAT LAAO sys-
tem. Compared with percutaneous endocardial LAAO 
devices such as the WATCHMAN (Boston Scientific 
Corporation, Natick, Massachusetts) and Amplatzer (St. 
Jude Medical, Inc., Saint Paul, Minnesota), systems, the 
LARIAT approach is epicardial, with only a polyester 
Table 5 LARIAT LAAO success and  durability and  proce-
dural and  late adverse events from  published series  with 
greater than  10 patients and  closed-chest ligation1 (Price 
and  Gibson 2014; Stone et  al. 2013; Bartus et  al. 2013; 
Massumi et al. 2013; Miller et al. 2014)
a Successful deployment of device with <5 mm leak by TEE/CT
b LAA leak <5 mm by last follow-up TEE/CT in those whom follow-up imaging 
available
c Events occurring prior to discharge and not including pericarditis
d Effusions requiring pericardiocentesis or vasopressor therapy
e Price et al. did not provide pericarditis rate
Number of patients
Device successa 313/334 (94 %)
Device durabilityb 222/226 (98 %)
Procedural adverse eventsc 64/334 (14.7 %)
 Death 1/334 (0.3 %)
 LAA laceration 6/334 (1.8 %)
 CVA/TIA 1/334 (0.3 %)
 Significant pericardial effusiond 25/334 (7.5 %)
 Complication with surgical intervention 8/334 (2.4 %)
 Pericarditise 15/180 (8.3 %)
 Pleural effusion 8/334 (2.4)
Late adverse events 33/334 (9.9 %)
 Death 6/334 (1.8 %)
 CVA/TIA 6/334 (1.8 %)
 Pleural effusion 6/334 (1.8 %)
 Pericardial effusion 10/334 (3.0 %)
 Thrombus in LA or LAA by TEE/CT 5/227 (2.2 %)
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suture left behind. Device embolization, noted in 1.2  % 
of patients in the PREVAIL trial of the WATCHMAN 
device, is not observed with LARIAT LAAO and late 
device erosion is not a concern (Holmes et  al. 2014). 
Intriguingly, involution of the LAA has been noted on 
CT imaging following LARIAT ligation and as early as 
4  weeks post-implant on autopsy findings, which may 
have a desirable impact on the long-term durability of 
this approach (Massumi et  al. 2013; Ellis et  al. 2015). 
LARIAT LAAO results in electrical isolation of the LAA, 
with post-procedural reduction in AF burden noted as 
well as increased maintenance of NSR observed when 
performed in conjunction with pulmonary vein isolation 
(Han et al. 2014; Afzal et al. 2015; Badhwar et al. 2015). 
In the PROTECT-AF and CAP registries of the WATCH-
MAN device, a less than 5 mm peri-device residual leak 
into the appendage defined procedural success, whereas 
several LARIAT series demonstrate no or minimal resid-
ual jet with a similar rate of procedural success (Bar-
tus et  al. 2013; Massumi et  al. 2013; Miller et  al. 2014; 
Holmes et  al. 2009; Reddy et  al. 2011). In case series, 
6.25–35.7 % of patients screened for LARIAT LAAO are 
excluded due to anatomical exclusions, while in the PRO-
TECT-AF experience of the WATCHMAN device, 38.9 % 
of patients screened for device placement were excluded 
for clinical and echocardiographic reasons, suggesting 
that a complement of LAAO approaches may be suitable 
to serve a clinically an anatomically diverse population of 
AF patients (Stone et  al. 2013; Bartus et  al. 2011, 2013; 
Holmes et al. 2009).
Widespread adoption of LARIAT LAAO is limited 
by lack of efficacy data, with utilization rationalized by 
presumed efficacy extrapolated from other appendage 
exclusion mechanisms, and minimal data regarding rate 
of long-term thrombotic events and procedural compli-
cations. Theoretically, AC after LARIAT LAAO is not 
required as only an epicardial suture is retained, how-
ever in the cumulative published experience, a TIA/CVA 
was observed in 1.8 % of patients in follow-up (Table 5) 
and AC or anti-platelet therapy was continued in 55 % of 
patients in the controlled Bartus et  al. series, reflecting 
uncertainty regarding residual thrombo-embolic risk in 
the absence of randomized trial data (Bartus et al. 2013). 
Comparatively, AC therapy was discontinued in most 
patients 45 days after WATCHMAN implant in the PRE-
VAIL and PROTECT-AF trials (Holmes et al. 2009, 2014). 
Several case reports detail thrombus at the site of the 
LAA orifice on surveillance imaging following LARIAT 
LAAO and thrombus was noted in 2.2 % of cases in the 
cumulative published experience (Table 3; Fig. 6a) (Price 
and Gibson 2014; Bartus et al. 2013; Briceno et al. 2013; 
Koranne et  al. 2015; Giedrimas et  al. 2013; Baker et  al. 
2013). Thrombus formation results from an inflamma-
tory environment at the ligation site, epithelial denuding 
at the LAA orifice during balloon catheter retrieval and 
sub-optimal suture deployment with a remnant throm-
bus-promoting static LAA chamber (Fig. 6b) (Bartus et al. 
2014). Additionally, recurrent LA-LAA communication 
after initial successful LARIAT LAAO can result from 
knot-loosening and tissue necrosis at the suture site and is 
another mechanism of thrombo-embolic complication. In 
case reports, late leaks have been treated successfully with 
alternate LAAO devices as repeat LARIAT ligation is not 
typically pursued due to potential pericardial adhesions 
developed after the initial procedure (Yeow et  al. 2013; 
Mosley et al. 2014; Di Biase et al. 2013; Pillai et al. 2014). 
The implications of residual leak are unknown, however in 
a review of 259 patients who underwent LARIAT ligation, 
14 % were noted to have recurrent LA-LAA communica-
tion at 1 year, compared with 21 % in patients undergoing 
WATCHMAN endocardial occlusion. Most commonly 
recurrent communication was of a central or ‘gunny sack’ 
Fig. 5 FDA MAUDE database review. a Types and frequencies of reported adverse events. b Outcomes after an adverse event; VT ventricular tachy-
cardia, LAC laceration, PERF perforation, OR operating room
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pattern, with no link with CVA observed (Pillarisetti et al. 
2015). Additionally, in a post hoc and underpowered 
analysis of the PROTECT-AF trial, increased thrombo-
embolic events were not noted in follow-up of patients 
with persistent peri-device flow with the WATCHMAN 
device (Viles-Gonzalez et al. 2012).
The incidence of peri-procedural complications during 
LARIAT LAAO is poorly delineated and derived from 
one controlled trial evaluating the device in 92 subjects 
and experience from reported case series. A peri-proce-
dural death rate of 0.3 % is noted in the cumulative pub-
lished LARIAT experience, however the FDA’s MAUDE 
database reports four procedure-related deaths, likely 
reflecting publication bias present in reported case-
series (Table 5; Fig. 5). The emergent surgery rate in the 
cumulative LARIAT experience was 2.4  % (8 patients) 
compared with 31 reports of emergent surgery in the 
MAUDE database. Notably, the emergency surgery rate 
was 1.6  % in the PROTECT-AF trial and 0.4  % in the 
PREVAIL trial (Holmes et  al. 2009, 2014). Uniquely, 
LARIAT LAAO results in a high rate of pericarditis due 
to pericardial manipulations and appendage necrosis and 
is also linked to the development of pleural effusions. 
Long-term implications of pericardial manipulation, 
inflammation and adhesion formation after LARIAT 
LAAO are not known. Paucity of data regarding real-
world rate of procedural complications and the device’s 
exclusively off-label use were critiqued in a recent JAMA 
review (Holmes et  al. 2009; Chatterjee et  al. 2015). The 
device is currently being studied in a multi-center obser-
vational trial evaluating procedural complication rate and 
short-term durability [ClinicalTrials.gov, NCT02059707].
A large, controlled trial of LARIAT LAAO would 
inform the incidence and mechanisms of various compli-
cations of LARIAT LAAO as well as possible means of 
improving upon these in a systematic fashion. Analysis of 
the PROTECT-AF trial and Continuing Access Registry 
of the WATCHMAN device allowed for advancements in 
operator training as well as device refinements and pro-
tocol modifications that resulted in significant improve-
ment in the safety and efficacy of the device (Holmes 
et al. 2009; Reddy et al. 2013). Further insight into ana-
tomical considerations that would enhance current inclu-
sion and exclusion criteria for LARIAT LAAO could also 
be obtained by a large-scale trial of the device. Delinea-
tion of an optimal AC regimen would inform and stand-
ardize post-procedural practice. Establishment of efficacy 
in reduction of thrombo-embolic events compared with 
Coumadin or NOACs is an important aim for future 
investigations and for meaningful comparison with other 
LAAO systems.
Conclusion
The LARIAT device is an epicardial approach to LAA 
ligation, with safety and efficacy studied in small clinical 
series. Epicardial ligation may have potential advantages 
over endocardial occlusion such as LAA involution and 
electrical isolation. True complications rates and proce-
dural strategies to prevent and manage complications, 
efficacy in reduction of thrombo-embolic events, opti-
mal patient selection and post-procedural AC regimens 
remain to be delineated for the LARIAT ligation system.
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